Your browser doesn't support javascript.
loading
Nanocarriers for oral delivery of biologics: small carriers for big payloads.
Cao, Yuxue; Rewatkar, Prarthana; Wang, Ran; Hasnain, Sumaira Z; Popat, Amirali; Kumeria, Tushar.
Afiliação
  • Cao Y; School of Pharmacy, The University of Queensland, Brisbane, QLD 4102, Australia.
  • Rewatkar P; School of Materials Science and Engineering, The University of New South Wales, Sydney, NSW 2052, Australia.
  • Wang R; Immunopathology Group, Mater Research Institute, The University of Queensland, Translational Research Institute, Brisbane, QLD 4102, Australia.
  • Hasnain SZ; Immunopathology Group, Mater Research Institute, The University of Queensland, Translational Research Institute, Brisbane, QLD 4102, Australia; Australian Infectious Diseases Research Centre, The University of Queensland, Brisbane, QLD 4102, Australia. Electronic address: sumaira.hasnain@mater.uq.ed
  • Popat A; School of Pharmacy, The University of Queensland, Brisbane, QLD 4102, Australia; Immunopathology Group, Mater Research Institute, The University of Queensland, Translational Research Institute, Brisbane, QLD 4102, Australia. Electronic address: a.popat@uq.edu.au.
  • Kumeria T; School of Pharmacy, The University of Queensland, Brisbane, QLD 4102, Australia; School of Materials Science and Engineering, The University of New South Wales, Sydney, NSW 2052, Australia; Australian Centre for NanoMedicine, University of New South Wales, Sydney, NSW 2052, Australia. Electronic add
Trends Pharmacol Sci ; 42(11): 957-972, 2021 11.
Article em En | MEDLINE | ID: mdl-34593258
ABSTRACT
Macromolecular therapeutics of biological origin, also known as biologics, have become one of the fastest-growing classes of drugs for management of a range of chronic and acute conditions. The majority of approved biologics are administered via the parenteral route and are thus expensive, have low patient compliance, and have high systemic toxicity. Therefore, tremendous efforts have been devoted to the development of carriers for oral delivery of biologics. This review evaluates key chemical (e.g. pH and enzymes) and physiological challenges to oral biologics delivery. We review the conventional formulation strategies and their limitations, followed by a detailed account of the progress on the use of nanocarriers used for oral biologics delivery, covering organic and inorganic nanocarriers. Lastly, we discuss limitations and opportunities presented by these emerging nanomaterials in oral biologics delivery.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Produtos Biológicos / Nanopartículas Limite: Humans Idioma: En Revista: Trends Pharmacol Sci Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Produtos Biológicos / Nanopartículas Limite: Humans Idioma: En Revista: Trends Pharmacol Sci Ano de publicação: 2021 Tipo de documento: Article